What is Newron Pharmaceuticals?
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals operates as a specialized biopharmaceutical entity dedicated to the research and development of novel therapies for patients suffering from diseases of the central nervous system and pain. The company maintains a robust pipeline focused on high-barrier-to-entry therapeutic areas, positioning itself as a critical player in the European life sciences sector. By integrating advanced pharmacological research with a disciplined clinical strategy, Newron aims to deliver transformative treatments that address the underlying mechanisms of neurological conditions.
How much funding has Newron Pharmaceuticals raised?
Newron Pharmaceuticals has raised a total of $25M across 3 funding rounds:
Series B
$8.1M
Other Financing Round
$8.2M
Debt
$8.7M
Series B (2005): $8.1M with participation from TVM Capital
Other Financing Round (2020): $8.2M led by European Investment Bank
Debt (2021): $8.7M supported by European Investment Bank
Key Investors in Newron Pharmaceuticals
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm focused on investing in innovative life science products and companies, providing capital and expertise to support the development of breakthrough therapies.
What's next for Newron Pharmaceuticals?
With the recent influx of capital, Newron Pharmaceuticals is well-positioned to accelerate its late-stage clinical programs and optimize its therapeutic pipeline. The strategic focus will likely shift toward commercialization readiness and the expansion of its intellectual property portfolio. As the company navigates the complexities of CNS drug development, the continued support from institutional lenders and venture partners will be instrumental in sustaining its research momentum. Future milestones will likely center on regulatory filings and the potential for strategic partnerships to enhance the global reach of its proprietary therapeutic candidates.
See full Newron Pharmaceuticals company page
